Shanghai InnoStar Bio-tech Co (SHSE:688710) Notes Receivable: ¥0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688710 Shanghai InnoStar Bio-tech Co Ltd SHSE:688710
35 GF Score
Price ¥75.04
! 8 Warning Signs
View Full Analysis

What is Shanghai InnoStar Bio-tech Co Notes Receivable?

Shanghai InnoStar Bio-tech Co SHSE:688710 +8.28% 35 Notes Receivable is ¥0.0 Mil as of Mar. 2026. GuruFocus rates SHSE:688710 with a GF Score™ of 35/100. The stock has 8 warning signs investors should review.

Shanghai InnoStar Bio-tech Co's Notes Receivable for the quarter that ended in Mar. 2026 was ¥0.0 Mil.


Shanghai InnoStar Bio-tech Co Notes Receivable Related Terms


Shanghai InnoStar Bio-tech Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Shanghai InnoStar Bio-tech Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai InnoStar Bio-tech Co Notes Receivable Chart

Shanghai InnoStar Bio-tech Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Shanghai InnoStar Bio-tech Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:688710
35GF Score
Shanghai InnoStar Bio-tech Co Ltd SHSE:688710
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai InnoStar Bio-tech Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ¥0.0 Mil mean?
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a Notes Receivable of ¥0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Shanghai InnoStar Bio-tech Co and its competitors.
Is Shanghai InnoStar Bio-tech Co's Notes Receivable too high?
Shanghai InnoStar Bio-tech Co's current Notes Receivable is ¥0.0 Mil. Overall, Shanghai InnoStar Bio-tech Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai InnoStar Bio-tech Co's Notes Receivable compare to LLY and JNJ?
Shanghai InnoStar Bio-tech Co's Notes Receivable of ¥0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Shanghai InnoStar Bio-tech Co and its competitors. Shanghai InnoStar Bio-tech Co's current Notes Receivable is ¥0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai InnoStar Bio-tech Co stock overvalued right now?
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a current Notes Receivable of ¥0.0 Mil. The current Notes Receivable is ¥0.0 Mil. Shanghai InnoStar Bio-tech Co's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Shanghai InnoStar Bio-tech Co (SHSE:688710), the current Notes Receivable is ¥0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shanghai InnoStar Bio-tech Co Business Description

Address No. 199 Guo Shoujing Road, Room 106, Pilot Free Trade Zone, Shanghai, CHN, 201203
Shanghai InnoStar Bio-tech Co Ltd is a comprehensive research and development services (CRO) enterprise that specializes in providing biomedical non-clinical research services.
35GF Score

Get the complete analysis for SHSE:688710

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥75.04
Price